| Market Capitalization (Millions $) |
3,585 |
| Shares
Outstanding (Millions) |
72 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
459 |
| Net Income (TTM) (Millions $) |
-63 |
| Cash Flow (TTM) (Millions $) |
34 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Viropharma Inc. was a pharmaceutical company that focused on developing and commercializing therapies for rare diseases. It was founded in 1994 and headquartered in Pennsylvania, United States. The company specialized in the development of antiviral drugs and treatments for diseases such as cytomegalovirus (CMV) and hereditary angioedema.
Viropharma's primary product was Cinryze, a medication used for the treatment and prevention of hereditary angioedema (HAE) attacks. HAE is a rare genetic disorder that results in recurrent episodes of severe swelling in various body parts. Cinryze was approved by the U.S. Food and Drug Administration (FDA) in 2008 and became a significant revenue generator for Viropharma.
In addition to Cinryze, Viropharma also developed and marketed other products, including Vancocin, an antibiotic used for the treatment of severe gastrointestinal infections caused by Clostridium difficile.
Viropharma faced several challenges in its history, including patent litigations and competitive pressures. In 2013, the company was acquired by Shire Pharmaceuticals, a global biotechnology company. Shire later merged with Takeda Pharmaceutical Company.
Overall, Viropharma Inc. played a crucial role in developing therapies for rare diseases and improving the quality of life for patients suffering from these conditions before its acquisition.
|
0.000%